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Advances in the Genetics of Type 2 Diabetes Mellitus in the Light of Personalized Healthcare
Diabetes is a chronic disorder of glucose homeostasis that affects >170 million people worldwide, and this figure is expected to double in the next 20 years. The majority of diabetes (~90%) is type 2 diabetes (T2D), caused by a combination of impaired insulin secretion from pancreatic beta cells and insulin resistance of the peripheral target tissues, especially muscle and liver. Historically, T2D has been considered a disease of late-adulthood onset, rarely observed in individuals under the age of 50. However, recent years have seen a steep increase in disease prevalence among children and adolescents, which has mainly been attributed to the unprecedentedly high levels of obesity in these groups.
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Clinical Complexity of Type 2 Diabetes
Clinically, one can distinguish three states-normal, impaired glucose tolerance, and overt diabetes-characterized by specific cut-offs of blood glucose levels either while fasting or after an oral glucose load. However, T2D
is a clinically heterogeneous disease often associated with complicating features of the metabolic syndrome such as obesity, dyslipidemia, hypertension, insulin resistance, and/or hyperinsulinemia. These physiological abnormalities may have overlapping molecular and genetic causes to further complicate diagnosis and treatment options. Many but not all patients develop comorbidities, including retinopathy, nephropathy, neuropathies, and cardiovascular disease. The potential for these unpredictable manifestations of the disease cannot be assessed during initial management, potentially leading to sub-optimal clinical care. 2 Today, a physician may choose from a panel of seven drug classes, roughly grouped into four areas of action: increase of insulin secretion by the pancreas (sulfonylurea, meglitinides, exenatide, dipeptidyl peptidase-4 inhibitors), decreased glucose absorption by the intestines (α-glucosidase inhibitors), inhibition of glucose production in the liver (biguanide), and enhanced insulin sensitivity in adipose and peripheral tissues (thiazolidinediones). Thus, current medical management of T2D can be a lengthy and costly trial-and-error method before good glucose homeostasis is achieved.
Genetic Complexity of Type 2 Diabetes
Genetic factors are known to play an important part in the development of T2D, as exemplified by rare monogenic subtypes, the high prevalence in particular ethnic groups, and its modification by genetic admixture and the difference in concordance rates between monozygotic and dizygotic twins. Program, TCF7L2 variation is strongly associated with rates of progression from impaired glucose tolerance to diabetes. 18 The exact role of TCF7L2 in the pathophysiology of diabetes is still largely unknown.
Monogenic Forms of Type 2 Diabetes

Maturity-onset Diabetes of the Young
TCF7L2 is widely expressed and involved in the Wnt signalling cascade.
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The predominant intermediate phenotype associated with TCF7L2 variation is impaired insulin secretion, consistent with the replicated observation that the TCF7L2 association is greater among lean than obese T2D subjects. Table 1 ). The Extensive resequencing and fine-mapping will be required to identify the causative variants in those genes, and it might be possible that those variants will show somewhat larger effect sizes. Between all studies, the number of replicated T2D susceptibility loci has now climbed from three to eight.
Clearly, from those first genome-wide association scan results, it can be anticipated that many more susceptibility genes have yet to be identified.
Interestingly, functional evaluation of all genes identified to date show that defects in pancreatic function seem to be the primary cause of T2D. 
Personalized Treatment
As discussed above, there is now a choice of drugs available that can be used to treat T2D either as stand-alone or combination treatment. It stands to reason that differences in the genetic make-up of individuals translate into differences in efficacy for these drugs. At least some of the genes that have been and will be identified as diabetes genes will contribute to such differences. Therefore, pharmacogenetic testing to establish such differences in response to a drug are a logical next step in the analysis of 
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It stands to reason that the newly discovered genes could lead to similar results, providing new tools to guide the choice of treatment. To achieve this, clinical trials on a similar scale to the association studies will be needed. Also, given the relatively modest effect sizes reported to date, multi-gene models rather than single gene calculations may be necessary.
Prediction for Prevention
The second large block of application is the prevention of diabetes through early prediction. 28 To assess the applicability of these findings to the general population, large prospective cohort studies will be needed. In this respect, considerable efforts have been 
